Medshine Discovery Inc. has synthesized mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1; HPK1; MEKKK1) inhibitors reported to be useful for the treatment of cancer.
Beigene Ltd. and Ensem Therapeutics Inc. have announced an agreement for Beigene to acquire an exclusive global license to an IND application-ready oral cyclin-dependent kinase 2 (CDK2) inhibitor.
Medicovestor Inc. has successfully completed an oversubscribed seed financing round with the aim of advancing its antibody-drug conjugate (ADC) platforms and drug candidates.
Arigenx Therapeutics Co. Ltd. has divulged substituted pyrimidine hydrazide compounds acting as aryl hydrocarbon receptor (AhR) antagonists reported to be useful for the treatment of cancer.
Erasca Inc. has synthesized tricyclic pyridones and pyrimidones acting as GTPase KRAS (G12C mutant) inhibitors reported to be useful for the treatment of cancer.
Astrazeneca AB has disclosed bicyclic heteroaromatic compounds acting as transcriptional enhancer factor (TEAD) and TEAD-4 inhibitors reported to be useful for the treatment of cancer.
Voltron Therapeutics Inc., a portfolio company of Lucius Partners LLC, has finalized the protocol for a preclinical dose-ranging efficacy study of VTX-0P4, a protein-based cancer vaccine targeting prostate stem cell antigen (PSCA), a key target in the treatment of prostate cancer.
Newco T-Therapeutics Ltd. has raised £48 million (US$59 million) in a series A to advance development of T-cell receptors generated by its transgenic mouse platform for the treatment of solid tumors, autoimmune diseases and infections. In cancer, the specificity of T-Therapeutics’ molecules will overcome shortcomings of immuno-oncology drugs such as checkpoint inhibitors that stimulate a response to some cancer neo-antigens but are unable to recognize cancer-specific self-antigens.
Graviton Bioscience BV has described Rho kinase 2 (ROCK 2; ROCKα) inhibitors reported to be useful for the treatment of cancer, fibrosis, autoimmune, lung, cardiovascular, eye, inflammatory and neurological disorders.
Legochem Biosciences Inc. has synthesized Toll-like receptor 7 (TLR7) and/or TLR8 agonists reported to be useful for the treatment of cancer, HIV infection, and hepatitis B virus infection.
RSS
